Categories: News

Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern Time

ATLANTA, Feb. 17, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, prior to the market open.

Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

Participants are asked to pre-register for the call.

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

The conference call will also be available through a live webcast, which is also available through the company’s website.

A webcast replay of the call will be available approximately one hour after the end of the call through May 24, 2022. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 2238986. The telephonic replay will be available until March 10, 2022.

About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com  
For investor inquiries:
Scott Gordon
for Alimera Sciences 
scottg@coreir.com

Staff

Recent Posts

Through High-Profile Ambassadors and Major Partnerships, ZetrOZ Systems Expanded Reach of sam Device in 2025

The leader in sports medicine healing innovations worked with athletes, athletic trainers, physicians and foundations…

3 hours ago

Scott Leune Names 2026 Sponsors Selected to Support Dental Practice Growth and Operations

SAN ANTONIO, Dec. 29, 2025 /PRNewswire/ -- Scott Leune Education today announced its 2026 sponsors,…

6 hours ago

New Horizon Medical Solutions Announces the Acquisition of the Applied Tissue Technologies Business Assets

New Horizon Medical Solutions acquires transparent negative pressure wound therapy device and micro grafting kit…

6 hours ago

Medical Care Technologies (OTC PINK:MDCE) Achieves Global Distribution Approval from Apple’s iOS App Store

MESA, AZ / ACCESS Newswire / December 29, 2025 / Medical Care Technologies Inc. (OTC…

6 hours ago